{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:41:16Z","timestamp":1783676476839,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shanghai Pulmonary Hospital Fund","award":["FKLY20004 and FKCX2304"],"award-info":[{"award-number":["FKLY20004 and FKCX2304"]}]},{"name":"Shanghai Pulmonary Hospital Fund","award":["FKLY20004 and FKCX2304"],"award-info":[{"award-number":["FKLY20004 and FKCX2304"]}]},{"name":"Shanghai Pulmonary Hospital Fund","award":["FKLY20004 and FKCX2304"],"award-info":[{"award-number":["FKLY20004 and FKCX2304"]}]},{"name":"Shanghai Pulmonary Hospital Fund","award":["FKLY20004 and FKCX2304"],"award-info":[{"award-number":["FKLY20004 and FKCX2304"]}]},{"name":"Shanghai Pulmonary Hospital Fund","award":["FKLY20004 and FKCX2304"],"award-info":[{"award-number":["FKLY20004 and FKCX2304"]}]},{"name":"Shanghai Pulmonary Hospital Fund","award":["FKLY20004 and FKCX2304"],"award-info":[{"award-number":["FKLY20004 and FKCX2304"]}]},{"name":"Shanghai Pulmonary Hospital Fund","award":["FKLY20004 and FKCX2304"],"award-info":[{"award-number":["FKLY20004 and FKCX2304"]}]},{"name":"Shanghai Pulmonary Hospital Fund","award":["FKLY20004 and FKCX2304"],"award-info":[{"award-number":["FKLY20004 and FKCX2304"]}]},{"name":"Shanghai Pulmonary Hospital Fund","award":["FKLY20004 and FKCX2304"],"award-info":[{"award-number":["FKLY20004 and FKCX2304"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-HR2019-0451"],"award-info":[{"award-number":["Y-HR2019-0451"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"crossref","award":["2023ZKZD33"],"award-info":[{"award-number":["2023ZKZD33"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"crossref","award":["2023ZKZD33"],"award-info":[{"award-number":["2023ZKZD33"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"crossref","award":["2023ZKZD33"],"award-info":[{"award-number":["2023ZKZD33"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"crossref","award":["2023ZKZD33"],"award-info":[{"award-number":["2023ZKZD33"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"crossref","award":["2023ZKZD33"],"award-info":[{"award-number":["2023ZKZD33"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"crossref","award":["2023ZKZD33"],"award-info":[{"award-number":["2023ZKZD33"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82125001"],"award-info":[{"award-number":["82125001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82125001"],"award-info":[{"award-number":["82125001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82125001"],"award-info":[{"award-number":["82125001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82125001"],"award-info":[{"award-number":["82125001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82125001"],"award-info":[{"award-number":["82125001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82125001"],"award-info":[{"award-number":["82125001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82125001"],"award-info":[{"award-number":["82125001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04250-4","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T17:09:51Z","timestamp":1752858591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA\u2013IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Shuyu","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxin","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minwei","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinsheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huansha","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lele","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"issue":"3","key":"4250_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4250_CR2","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353.","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"4250_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-024-01861-w","volume":"9","author":"H Xia","year":"2024","unstructured":"Xia H, Zhang H, Ruan Z, Zhang H, Sun L, Chen H, Zhou Y, Zhang L, Bian D, Zhu X, et al. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study. Signal Transduct Target Ther. 2024;9(1):145.","journal-title":"Signal Transduct Target Ther"},{"key":"4250_CR4","doi-asserted-by":"crossref","unstructured":"Aigner C, Batirel H, Huber RM, Jones DR, Sihoe ADL, \u0160tupnik T, Brunelli A: Resectable non-stage IV nonsmall cell lung cancer: the surgical perspective. Eur Respir Rev 2024, 33(171).","DOI":"10.1183\/16000617.0195-2023"},{"issue":"129","key":"4250_CR5","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1183\/09059180.00003913","volume":"22","author":"L Lang-Lazdunski","year":"2013","unstructured":"Lang-Lazdunski L. Surgery for nonsmall cell lung cancer. Eur Respir Rev. 2013;22(129):382\u2013404.","journal-title":"Eur Respir Rev"},{"issue":"21","key":"4250_CR6","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"6","key":"4250_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(6):491\u2013503.","journal-title":"N Engl J Med"},{"issue":"3","key":"4250_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","volume":"331","author":"S Lu","year":"2024","unstructured":"Lu S, Zhang W, Wu L, Wang W, Zhang P, Fang W, Xing W, Chen Q, Yang L, Mei J, et al. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. JAMA. 2024;331(3):201\u201311.","journal-title":"JAMA"},{"issue":"1","key":"4250_CR9","doi-asserted-by":"publisher","first-page":"1865653","DOI":"10.1080\/2162402X.2020.1865653","volume":"10","author":"E Dudnik","year":"2021","unstructured":"Dudnik E, Moskovitz M, Rottenberg Y, Lobachov A, Mandelboim R, Shochat T, Urban D, Wollner M, Nechushtan H, Rotem O, et al. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) \u226550%: real-world data. Oncoimmunology. 2021;10(1):1865653.","journal-title":"Oncoimmunology"},{"issue":"3","key":"4250_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00262-021-03029-9","volume":"71","author":"H Takumida","year":"2022","unstructured":"Takumida H, Horinouchi H, Masuda K, Shinno Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, Ohe Y. Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression. Cancer Immunol Immunother. 2022;71(3):737\u201346.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4250_CR11","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41467-025-57184-z","volume":"16","author":"C Yi","year":"2025","unstructured":"Yi C, Bian D, Wang J, Hu S, Sun L, Yan Y, Wang S, Shen Z, Yu H, Yang Y, et al. Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial. Nat Commun. 2025;16(1):1932.","journal-title":"Nat Commun"},{"issue":"24","key":"4250_CR12","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1158\/1078-0432.CCR-24-1561","volume":"30","author":"K Aokage","year":"2024","unstructured":"Aokage K, Koyama S, Kumagai S, Nomura K, Shimada Y, Yoh K, Wakabayashi M, Fukutani M, Furuya H, Miyoshi T, et al. Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY). Clin Cancer Res. 2024;30(24):5584\u201392.","journal-title":"Clin Cancer Res"},{"issue":"43","key":"4250_CR13","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012;109(43):17561\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"4250_CR14","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov. 2021;11(6):1368\u201397.","journal-title":"Cancer Discov"},{"issue":"3","key":"4250_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305\u201314.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"4250_CR16","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonz\u00e1lez-Larriba JL, Mart\u00ednez-Mart\u00ed A, Bernab\u00e9 R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, et al. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(6):504\u201313.","journal-title":"N Engl J Med"},{"issue":"10","key":"4250_CR17","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/s41591-022-01962-5","volume":"28","author":"JE Chaft","year":"2022","unstructured":"Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022;28(10):2155\u201361.","journal-title":"Nat Med"},{"issue":"10459","key":"4250_CR18","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","volume":"404","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404(10459):1240\u201352.","journal-title":"Lancet"},{"issue":"6","key":"4250_CR19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jinf.2022.10.016","volume":"85","author":"T Chailangkarn","year":"2022","unstructured":"Chailangkarn T, Teeravechyan S, Attasombat K, Thaweerattanasinp T, Sunchatawirul K, Suwanwattana P, Pongpirul K, Jongkaewwattana A. Monkeypox virus productively infects human induced pluripotent stem cell-derived astrocytes and neural progenitor cells. J Infect. 2022;85(6):702\u201369.","journal-title":"J Infect"},{"issue":"4","key":"4250_CR20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","volume":"17","author":"S Ren","year":"2022","unstructured":"Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, et al. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. J Thorac Oncol. 2022;17(4):544\u201357.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"4250_CR21","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jamaoncol.2023.2751","volume":"9","author":"J Lei","year":"2023","unstructured":"Lei J, Zhao J, Gong L, Ni Y, Zhou Y, Tian F, Liu H, Gu Z, Huang L, Lu Q, et al. Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial. JAMA Oncol. 2023;9(10):1348\u201355.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4250_CR22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ijc.33976","volume":"151","author":"J Liu","year":"2022","unstructured":"Liu J, Li J, Lin W, Shao D, Depypere L, Zhang Z, Li Z, Cui F, Du Z, Zeng Y, et al. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study. Int J Cancer. 2022;151(1):128\u201337.","journal-title":"Int J Cancer"},{"issue":"1","key":"4250_CR23","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1038\/s41467-022-33080-8","volume":"13","author":"WT Ju","year":"2022","unstructured":"Ju WT, Xia RH, Zhu DW, Dou SJ, Zhu GP, Dong MJ, Wang LZ, Sun Q, Zhao TC, Zhou ZH, et al. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. Nat Commun. 2022;13(1):5378.","journal-title":"Nat Commun"},{"issue":"7","key":"4250_CR24","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.ccell.2024.05.024","volume":"42","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Pan Y, Yang X, Zhao Y, Han G, Pang Q, Zhang Z, Wang Q, Yao J, Wang H, et al. Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial. Cancer Cell. 2024;42(7):1258-1267.e1252.","journal-title":"Cancer Cell"},{"issue":"3","key":"4250_CR25","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jtho.2019.10.022","volume":"15","author":"WL Tan","year":"2020","unstructured":"Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, et al. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. J Thorac Oncol. 2020;15(3):324\u201343.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4250_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1001\/jamaoncol.2022.5389","volume":"9","author":"AP Desai","year":"2023","unstructured":"Desai AP, Adashek JJ, Reuss JE, West HJ, Mansfield AS. Perioperative Immune Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer: A Review. JAMA Oncol. 2023;9(1):135\u201342.","journal-title":"JAMA Oncol"},{"issue":"6","key":"4250_CR27","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jtho.2023.02.019","volume":"18","author":"J Zhao","year":"2023","unstructured":"Zhao J, Zhao L, Guo W, Wang S, Tao X, Li L, Mao Y, Tan F, Gao Y, Wu N, et al. Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial. J Thorac Oncol. 2023;18(6):780\u201391.","journal-title":"J Thorac Oncol"},{"issue":"34","key":"4250_CR28","first-page":"4095","volume":"38","author":"C Lan","year":"2020","unstructured":"Lan C, Shen J, Wang Y, Li J, Liu Z, He M, Cao X, Ling J, Huang J, Zheng M, et al. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm. Phase II Trial J Clin Oncol. 2020;38(34):4095\u2013106.","journal-title":"Phase II Trial J Clin Oncol"},{"issue":"4","key":"4250_CR29","first-page":"1003","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, Shao G, Zhang Y, Xu L, Yin T, et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label. Phase II Trial Clin Cancer Res. 2021;27(4):1003\u201311.","journal-title":"Phase II Trial Clin Cancer Res"},{"issue":"3","key":"4250_CR30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(21)00378-2","volume":"7","author":"X Meng","year":"2022","unstructured":"Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, Yang X, Shi P, Yang J, Yin X, et al. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):245\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"4250_CR31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jtho.2023.10.014","volume":"19","author":"L Wang","year":"2024","unstructured":"Wang L, Luo Y, Ren S, Zhang Z, Xiong A, Su C, Zhou J, Yu X, Hu Y, Zhang X, et al. A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC. J Thorac Oncol. 2024;19(3):465\u201375.","journal-title":"J Thorac Oncol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04250-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04250-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04250-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:21:33Z","timestamp":1757254893000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04250-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4250"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04250-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5558939\/v1","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"1 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was rigorously designed in compliance with the Declaration of Helsinki and Good Clinical Practice guidelines, receiving ethical approval from the institutional review boards of all participating centers (No: 19217XW-1). Prior to enrollment, all patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate."}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"429"}}